{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:37:39Z","timestamp":1792687059848,"version":"4.5.0"},"reference-count":116,"publisher":"FapUNIFESP (SciELO)","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Soc. Bras. Med. Trop."],"DOI":"10.1590\/0037-8682-0504-2023","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T10:10:18Z","timestamp":1711361418000},"source":"Crossref","is-referenced-by-count":8,"title":["Isoniazid use, effectiveness, and safety for treatment of latent tuberculosis infection: a systematic review"],"prefix":"10.1590","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9875-4334","authenticated-orcid":false,"given":"B\u00e1rbara Manuella Cardoso","family":"Sodr\u00e9-Alves","sequence":"first","affiliation":[{"name":"Universidade de Bras\u00edlia,  Brasil; Universidade de Bras\u00edlia,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2727-2933","authenticated-orcid":false,"given":"Melina Mafra","family":"Toledo","sequence":"additional","affiliation":[{"name":"Universidade de Bras\u00edlia,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7757-7519","authenticated-orcid":false,"given":"Ivan Ricardo","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"Universidade de Bras\u00edlia,  Brasil; Universidade de Bras\u00edlia,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6856-4094","authenticated-orcid":false,"given":"Wildo Navegantes de","family":"Ara\u00fajo","sequence":"additional","affiliation":[{"name":"Universidade de Bras\u00edlia,  Brasil; Universidade de Bras\u00edlia,  Brasil; Universidade de Bras\u00edlia,  Brasil; Instituto Nacional de Ci\u00eancia e Tecnologia para Avalia\u00e7\u00e3o de Tecnologias em Sa\u00fade,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6180-7527","authenticated-orcid":false,"given":"Noemia Urruth Le\u00e3o","family":"Tavares","sequence":"additional","affiliation":[{"name":"Universidade de Bras\u00edlia,  Brasil; Universidade de Bras\u00edlia,  Brasil; Universidade de Bras\u00edlia,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref1","series-title":"Global tuberculosis report 2023","year":"2023"},{"issue":"3","key":"ref2","first-page":"60","article-title":"Tuberculose ativa versus Tuberculose Latente: uma revis\u00e3o de literatura","volume":"4","author":"Busatto C","year":"2015","journal-title":"J Infect Control"},{"key":"ref3","series-title":"Global tuberculosis report 2017","year":"2017"},{"issue":"329","key":"ref4","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2944","article-title":"Back to the future: Rethinking global control of tuberculosis","volume":"8","author":"Br Bloom","year":"2016","journal-title":"Sci Transl Med"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S2213-2600(19)30418-7","article-title":"WHO global progress report on tuberculosis elimination","volume":"8","author":"Harding E","year":"2020","journal-title":"Lancet Respir Med"},{"key":"ref6","series-title":"Guidelines on the management of latent tuberculosis infection","year":"2015"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1183\/13993003.01245-2015","article-title":"Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries","volume":"46","author":"Getahun H","year":"2015","journal-title":"Eur Respir J"},{"key":"ref8","series-title":"Manual de Recomenda\u00e7\u00f5es para o Controle da Tuberculose no Brasil","year":"2019"},{"key":"ref9","first-page":"1","article-title":"Updates on the risk factors for latent tuberculosis reactivation and their managements","volume":"5","author":"Ai JW","year":"2016","journal-title":"Emerg Microbes Infect"},{"key":"ref10","article-title":"Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data","volume":"8","author":"Ross JM","year":"2021","journal-title":"Lancet HIV"},{"issue":"5","key":"ref11","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/QAI.0000000000002497","article-title":"Evaluation of 6-Month Versus Continuous Isoniazid Preventive Therapy for Mycobacterium tuberculosis in Adults Living With HIV\/AIDS in Malawi","volume":"85","author":"Hsieh YL","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref12","series-title":"Global tuberculosis report 2020","year":"2020"},{"issue":"2","key":"ref13","article-title":"Barriers to treatment adherence for individuals with latent tuberculosis infection: A systematic search and narrative synthesis of the literature","volume":"33","author":"Liu Y","year":"2018","journal-title":"Int J Health Plann Manage"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-017-2377-x","article-title":"Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses","volume":"17","author":"Pease C","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"6","key":"ref15","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/pds.4423","article-title":"A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection","volume":"27","author":"Pease C","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-016-1550-y","article-title":"Initiation and completion rates for latent tuberculosis infection treatment: a systematic review","volume":"16","author":"Sandgren A","year":"2016","journal-title":"BMC Infect Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-016-1549-4","article-title":"Interventions for improving adherence to treatment for latent tuberculosis infection: a systematic review","volume":"16","author":"Stuurman AL","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"n71","key":"ref18","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Matthew JP Joanne EMK","year":"2021","journal-title":"BMJ"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-2-4","article-title":"PROSPERO at one year: an evaluation of its utility","volume":"2","author":"Booth A","year":"2013","journal-title":"Systematic Reviews"},{"issue":"10","key":"ref20","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1177\/1049732312452938","article-title":"Beyond PICO: The SPIDER tool for qualitative evidence synthesis","volume":"22","author":"Cooke A","year":"2012","journal-title":"Qual Health Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani M","year":"2016","journal-title":"Systematic Reviews"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The Measurement of Observer Agreement for Categorical Data","volume":"33","author":"Landis JR","year":"1977","journal-title":"Biometrics"},{"key":"ref23","series-title":"Study Quality Assessment Tools. National Heart, Lung, and Blood Institute Washington","year":"2021"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2334-10-267","article-title":"Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain","volume":"10","author":"Diaz A","year":"2010","journal-title":"BMC Infect Dis"},{"issue":"3","key":"ref25","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1086\/600394","article-title":"A Retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central Massachusetts","volume":"49","author":"Young H","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref26","article-title":"Adherence to treatment of latent tuberculosis infection in a clinical population in New York City","volume":"14","author":"Li J","year":"2010","journal-title":"Int J Infect Dis"},{"issue":"3","key":"ref27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1503\/cmaj.091824","article-title":"Adverse events associated with treatment of latent tuberculosis in the general population","volume":"183","author":"Smith BM","year":"2011","journal-title":"CMAJ"},{"issue":"5","key":"ref28","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/cid\/ciz1157","article-title":"Clinical characteristics of active tuberculosis diagnosed after starting treatment for latent tuberculosis infection","volume":"71","author":"Flynn AG","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"3","key":"ref29","first-page":"306","article-title":"Completing tuberculosis prophylaxis in jail: Targeting treatment and comparison of rifampin\/pyrazinamide with isoniazid regimens","volume":"8","author":"Lincoln T","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"ref30","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/IPC.0000000000000518","article-title":"Completion Rate and Safety of 12-Dose Isoniazid and Rifapentine for Latent Tuberculosis in a Predominantly Refugee Cohort","volume":"25","author":"Sweeney TL","year":"2017","journal-title":"Infect Dis Clin Pract"},{"issue":"1","key":"ref31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofv220","article-title":"Completion rate and side-effect profile of three-month isoniazid and rifapentine treatment for latent tuberculosis infection in an Urban county jail","volume":"3","author":"Juarez-Reyes M","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"ref32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.17269\/cjph.104.3643","article-title":"Completion rates of treatment for latent tuberculosis infection in Quebec, Canada From 2006 to 2010","volume":"104","author":"Rivest P","year":"2013","journal-title":"Can J Public Health"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"71S","DOI":"10.1177\/0033354919826557","article-title":"Completion Rates, Adverse Effects, and Costs of a 3-Month and 9-Month Treatment Regimen for Latent Tuberculosis Infection in California Inmates, 2011-2014","volume":"134","author":"Wheeler C","year":"2019","journal-title":"Public Health Reports"},{"issue":"3","key":"ref34","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/lt.22203","article-title":"Detection and management of latent tuberculosis in liver transplant patients","volume":"17","author":"Jafri SM","year":"2011","journal-title":"Liver Transplantation"},{"issue":"2","key":"ref35","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/cid\/ciz817","article-title":"Determinants of latent tuberculosis treatment acceptance and completion in healthcare personnel","volume":"71","author":"Swift MD","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"12","key":"ref36","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1086\/379513","article-title":"Effectiveness of Isoniazid Treatment for Latent Tuberculosis Infection among Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Injection Drug Users in Methadone Programs","volume":"37","author":"Scholten JN","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"3","key":"ref37","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1378\/chest.130.6.1712","article-title":"Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin","volume":"130","author":"Lardizabal A","year":"2006","journal-title":"Chest"},{"issue":"4","key":"ref38","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1086\/596606","article-title":"Evaluation of the Effect of Treatment of Latent Tuberculosis Infection on QuantiFERON-TB Gold Assay Results","volume":"30","author":"Pollock NR","year":"2009","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"5","key":"ref39","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1378\/chest.122.5.1609","article-title":"Factors associated with the treatment of latent tuberculosis infection among health-care workers at a midwestern teaching hospital","volume":"122","author":"Shukla SJ","year":"2002","journal-title":"Chest"},{"issue":"4","key":"ref40","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3122\/jabfm.2017.04.170070","article-title":"Factors that influence treatment completion for latent tuberculosis infection","volume":"30","author":"Eastment MC","year":"2017","journal-title":"J Am Board Fam Med"},{"issue":"17","key":"ref41","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1001\/archinte.166.17.1863","article-title":"Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: A retrospective study","volume":"166","author":"Page KR","year":"2006","journal-title":"Arch Intern Med"},{"issue":"11","key":"ref42","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.5588\/ijtld.18.0035","article-title":"Improved treatment completion with shorter treatment regimens for latent tuberculous infection","volume":"22","author":"Macaraig MM","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"ref43","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1378\/chest.09-0394","article-title":"Latent TB infection treatment acceptance and completion in the United States and Canada","volume":"137","author":"JrCR Horsburgh","year":"2010","journal-title":"Chest"},{"issue":"6","key":"ref44","doi-asserted-by":"crossref","first-page":"705","DOI":"10.17269\/s41997-019-00240-1","article-title":"Latent tuberculosis treatment completion rates from prescription drug administrative data","volume":"110","author":"Plourde PJ","year":"2019","journal-title":"Can J Public Health"},{"issue":"12","key":"ref45","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/cid\/cix725","article-title":"Management of Latent Tuberculosis Infection among Healthcare Workers: 10-Year Experience at a Single Center","volume":"65","author":"Arguello Perez E","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"7","key":"ref46","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/ijd.12679","article-title":"Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida","volume":"54","author":"Medina-Gil C","year":"2015","journal-title":"Int J Dermatol"},{"issue":"1","key":"ref47","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1378\/chest.123.1.102","article-title":"Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: Improved completion rates but more hepatotoxicity","volume":"123","author":"McNeill L","year":"2003","journal-title":"Chest"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2458-10-28","article-title":"Referrals for positive tuberculin tests in new health care workers and students: A retrospective cohort study","volume":"10","author":"Xu Y","year":"2010","journal-title":"BMC Public Health"},{"issue":"4","key":"ref49","doi-asserted-by":"crossref","first-page":"421","DOI":"10.5588\/ijtld.13.0688","article-title":"Risk factors for treatment default in close contacts with latent tuberculous infection","volume":"18","author":"Fiske CT","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"ref50","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1097\/TP.0000000000001329","article-title":"Twelve-week rifapentine plus isoniazid versus 9-month isoniazid for the treatment of latent tuberculosis in renal transplant candidates","volume":"101","author":"Simkins J","year":"2017","journal-title":"Transplantation"},{"issue":"3","key":"ref51","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1086\/505398","article-title":"Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection","volume":"43","author":"Cook PP","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"1","key":"ref52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-017-2245-8","article-title":"Treatment completion for latent tuberculosis infection: A retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine","volume":"17","author":"McClintock AH","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"2","key":"ref53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/tid.13244","article-title":"Treatment of latent tuberculosis infection with short-course regimens in potential living kidney donors","volume":"22","author":"Simkins J","year":"2020","journal-title":"Transpl Infect Dis"},{"issue":"3","key":"ref54","doi-asserted-by":"crossref","first-page":"1902048","DOI":"10.1183\/13993003.02048-2019","article-title":"Treatment with isoniazid or rifampin for latent tuberculosis infection: Population-based study of hepatotoxicity, completion and costs","volume":"55","author":"Ronald LA","year":"2020","journal-title":"Eur Respir J"},{"issue":"7","key":"ref55","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.bbmt.2020.03.013","article-title":"Latent Tuberculosis in Hematopoietic Stem Cell Transplantation: Diagnostic and Therapeutic Strategies to Prevent Disease Activation in an Endemic Population","volume":"26","author":"Bourlon C","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1590\/s1678-9946202062008","article-title":"Access and adherence to isoniazid preventive therapy and occurrence of active TB in a cohort of people living with HIV: A retrospective cohort study in Sao Paulo, Brazil","volume":"62","author":"Picone CM","year":"2020","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijid.2020.02.015","article-title":"Determinants of losses in the latent tuberculosis cascade of care in Brazil: A retrospective cohort study","volume":"93","author":"Ara\u00fajo NC","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"9","key":"ref58","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s00296-015-3249-6","article-title":"Follow-up results of isoniazid chemoprophylaxis during biological therapy in Colombia","volume":"35","author":"Cata\u00f1o JC","year":"2015","journal-title":"Rheumatol Int"},{"issue":"2","key":"ref59","first-page":"132","article-title":"Incidence of Latent Tuberculosis Infection in a study of household contacts treated in a General Hospital of the City of Buenos Aires","volume":"19","author":"Joza K","year":"2019","journal-title":"Rev Am med respir"},{"issue":"8","key":"ref60","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1016\/j.transproceed.2012.07.035","article-title":"Is isoniazid safe for liver transplant candidates with latent tuberculosis?","volume":"44","author":"Stucchi RSB","year":"2012","journal-title":"Transplant Proc"},{"issue":"8","key":"ref61","article-title":"Latent tuberculosis infection in persons with HIV\/AIDS, associated factors, and progression to active disease in a city in southern Brazil","volume":"33","author":"Santos DTD","year":"2017","journal-title":"Cad Saude Publica"},{"issue":"12","key":"ref62","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1111\/ajt.12470","article-title":"Results of implementation of preventive recommendations for tuberculosis after renal transplantation in an endemic area","volume":"13","author":"De Lemos AS","year":"2013","journal-title":"Am J Transplant"},{"issue":"1","key":"ref63","first-page":"3","article-title":"10 Years of Innovation in the Treatment of Latent Tuberculosis Infection: a Comparison Between Standard and Short Course Therapies in Directly Observed Therapy","volume":"13","author":"L\u00f3pez G","year":"2011","journal-title":"Rev Esp Sanid Penit"},{"key":"ref64","first-page":"4","article-title":"Adverse effects and adherence to treatment of rifampicine 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis","volume":"141","author":"Fresard I","year":"2011","journal-title":"Swiss Med Wkly"},{"issue":"5","key":"ref65","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.rmed.2013.01.017","article-title":"Cost-effectiveness of rifampin for 4 months and isoniazid for 6 months in the treatment of tuberculosis infection","volume":"107","author":"Pina JM","year":"2013","journal-title":"Respir Med"},{"issue":"10","key":"ref66","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/00007890-200211270-00006","article-title":"Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area","volume":"74","author":"Benito N","year":"2002","journal-title":"Transplantation"},{"issue":"4","key":"ref67","first-page":"647","article-title":"Failure to complete treatment for latent tuberculosis infection and medical-associated factors","volume":"39","author":"Sent\u00eds A","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"ref68","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1086\/422645","article-title":"Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment","volume":"39","author":"van Hest R","year":"2004","journal-title":"Clin Infect Dis"},{"key":"ref69","first-page":"1","article-title":"High rate of completion of preventive therapy for latent tuberculosis infection among asylum seekers in a Swiss Canton","volume":"143","author":"Sarivalasis A","year":"2013","journal-title":"Swiss Med Wkly"},{"issue":"7","key":"ref70","doi-asserted-by":"crossref","first-page":"903","DOI":"10.5588\/ijtld.12.0677","article-title":"Isoniazid preventive treatment: Predictors of adverse events and treatment completion","volume":"17","author":"Codecasa LR","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"ref71","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3390\/jcm9010101","article-title":"Latent Tuberculosis Infection Treatment Completion while Shifting Prescription from Isoniazid-Only to Rifampicin-Containing Regimens: A Two-Decade Experience in Milan, Italy","volume":"9","author":"Villa S","year":"2019","journal-title":"J Clin Med"},{"issue":"9","key":"ref72","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/apt.12037","article-title":"Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-\u03b1 inhibitors","volume":"36","author":"Papay P","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"ref73","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/ecco-jcc\/jjx080","article-title":"Serial tuberculosis screening in inflammatory bowel disease patients receiving anti-TNF\u03b1 therapy","volume":"11","author":"Abreu C","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"6","key":"ref74","first-page":"701","article-title":"Treatment completion in latent tuberculosis infection at specialist tuberculosis units in Spain","volume":"14","author":"Anibarro L","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"issue":"10","key":"ref75","first-page":"1127","article-title":"Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis","volume":"10","author":"Sichletidis L","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"ref76","doi-asserted-by":"crossref","first-page":"342","DOI":"10.5588\/ijtld.14.0554","article-title":"Comparison of LTBI treatment regimens for patients receiving anti-tumour necrosis factor therapy","volume":"19","author":"Park SJ","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"ref77","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3904\/kjim.2015.095","article-title":"Prospective Cohort Study of Latent Tuberculosis","volume":"31","author":"Park SH","year":"2016","journal-title":"Korean J Intern Med"},{"issue":"4","key":"ref78","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3947\/ic.2019.51.4.355","article-title":"Screening and treatment of latent tuberculosis infection among healthcare workers at a referral hospital in Korea","volume":"51","author":"Park SY","year":"2019","journal-title":"Infect Chemother"},{"issue":"1","key":"ref79","first-page":"1","article-title":"Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection","volume":"7","author":"Lee EH","year":"2017","journal-title":"Sci Rep"},{"issue":"8","key":"ref80","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/ecco-jcc\/jjy057","article-title":"A prospective study to monitor for tuberculosis during anti-tumour necrosis factor therapy in patients with inflammatory bowel disease and immune-mediated inflammatory diseases","volume":"12","author":"Lee CK","year":"2018","journal-title":"J Crohns Colitis"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.rmed.2019.09.004","article-title":"Completion rate of latent tuberculosis infection treatment in patients aged 65 years and older","volume":"157","author":"Noh CS","year":"2019","journal-title":"Respir Med"},{"issue":"2","key":"ref82","doi-asserted-by":"crossref","first-page":"62","DOI":"10.5152\/eurjrheumatol.2014.019","article-title":"Does isoniazid chemoprophylaxis increase the frequency of hepatotoxicity in patients receiving anti-TNF-\u03b1 agent with a disease-modifying antirheumatic drug?","volume":"1","author":"Cansu D\u00dc","year":"2014","journal-title":"Eur J Rheumatol"},{"issue":"34","key":"ref83","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004126","article-title":"Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan","volume":"95","author":"Huang YW","year":"2016","journal-title":"Medicine"},{"issue":"6","key":"ref84","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jmii.2017.04.001","article-title":"Efficacy of isoniazid salvage therapy for latent tuberculosis infection in patients with immune-mediated inflammatory disorders - A retrospective cohort study in Taiwan","volume":"51","author":"Huang SF","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"issue":"11","key":"ref85","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s00296-009-1170-6","article-title":"Follow-up results of 702 patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosis","volume":"30","author":"Cagatay T","year":"2010","journal-title":"Rheumatol Int"},{"issue":"4","key":"ref86","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10067-008-1067-x","article-title":"Increased risk of tuberculosis in patients treated with antitumor necrosis factor alpha","volume":"28","author":"Elbek O","year":"2009","journal-title":"Clin Rheumatol"},{"issue":"3","key":"ref87","doi-asserted-by":"crossref","first-page":"322","DOI":"10.5588\/ijtld.18.0448","article-title":"IPT in people living with HIV in Myanmar: A five-fold decrease in incidence of TB disease and all-cause mortality","volume":"23","author":"Kyaw NTT","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"ref88","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3390\/tropicalmed4020085","article-title":"Latent tuberculosis infection among healthcare workers in Duhok province: From screening to prophylactic treatment","volume":"4","author":"Almufty HB","year":"2019","journal-title":"Trop Med Infect Dis"},{"issue":"2","key":"ref89","first-page":"226","article-title":"Treatment of latent TB infection for close contacts as a complementary TB control strategy in Singapore","volume":"8","author":"Chee CBE","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"ref90","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1164\/rccm.200608-1109OC","article-title":"Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens","volume":"175","author":"Chee CB","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"ref91","doi-asserted-by":"crossref","first-page":"502","DOI":"10.7883\/yoken.JJID.2016.480","article-title":"QuantiFERON-TB Gold In-Tube Test for tuberculosis prevention in HIV-infected patients","volume":"70","author":"Khawcharoenporn T","year":"2017","journal-title":"Jpn J Infect Dis"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s10067-008-0867-3","article-title":"The evaluation of latent tuberculosis in rheumatologic diseases for anti-TNF therapy: Experience with 192 patients","volume":"27","author":"Hanta I","year":"2008","journal-title":"Clin Rheumatol"},{"key":"ref93","first-page":"11","article-title":"Does Isoniazid Preventive Therapy Provide Better Treatment Outcomes in HIV-Infected Individuals in Northern Ethiopia? A Retrospective Cohort Study","volume":"2020","author":"Atey TM","year":"2020","journal-title":"AIDS Res Treat"},{"issue":"3","key":"ref94","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1378\/chest.13-1232","article-title":"Effect of isoniazid therapy for latent tb infection on quantiferon-Tb gold in-Tube responses in adults with positive tuberculin skin test results in a high tb incidence area","volume":"145","author":"Johnson JL","year":"2014","journal-title":"Chest"},{"issue":"1","key":"ref95","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/QAI.0000000000001461","article-title":"Evaluation of the isoniazid preventive therapy care cascade among HIV-positive female sex workers in Mombasa, Kenya","volume":"76","author":"LaCourse SM","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"ref96","first-page":"935","article-title":"A controlled trial of community-wide isoniazid prophylaxis in Alaska","volume":"95","author":"Comstock GW","year":"1967","journal-title":"Am Rev Respir Dis"},{"key":"ref97","first-page":"821","article-title":"The Effect of Isoniazid Prophylaxis on Tuberculosis Morbidity among Household Contacts of Previously Known Cases of Tuberculosis","volume":"85","author":"Mount FW","year":"1962","journal-title":"Am Rev Respir Dis"},{"key":"ref98","first-page":"161","article-title":"A controlled trial of isoniazid prophylaxis in mental institutions","volume":"88","author":"Ferebee SH","year":"1963","journal-title":"Nursing Research"},{"key":"ref99","first-page":"490","article-title":"Tuberculosis Morbidity in a Controlled Trial of the Prophylactic Use of Isoniazid among Household Contacts","volume":"85","author":"Ferebee SH","year":"1962","journal-title":"Am Rev Respir Dis"},{"issue":"3","key":"ref100","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-2667(18)30002-1","article-title":"Determinants of tuberculosis trends in six Indigenous populations of the USA, Canada, and Greenland from 1960 to 2014: a population-based study","volume":"3","author":"Dehghani K","year":"2018","journal-title":"Lancet Public Health"},{"key":"ref101","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0266803","article-title":"Tuberculosis and isoniazid prophylaxis among adult HIV positive patients on ART in Northwest Ethiopia","volume":"17","author":"Geremew D","year":"2022","journal-title":"PloS one"},{"issue":"1","key":"ref102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"69","author":"Sterling TR","year":"2020","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"ref103","article-title":"Use of Isoniazid Monotherapy in Comparison to Rifamycin-Based Regimen for the Treatment of Patients With Latent Tuberculosis: A Systematic Review","volume":"14","author":"Noreen N","year":"2022","journal-title":"Cureus"},{"issue":"3-4","key":"ref104","first-page":"167","article-title":"Compliance with latent tuberculosis treatment: a public health challenge","volume":"153","author":"Bishara H","year":"2014","journal-title":"Harefuah"},{"issue":"1","key":"ref105","doi-asserted-by":"crossref","first-page":"31","DOI":"10.5588\/ijtld.14.0373","article-title":"Latent tuberculous infection in the United States and Canada: who completes treatment and why?","volume":"19","author":"Hirsch-Moverman Y","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"issue":"11","key":"ref106","first-page":"CD006594v","article-title":"Reminder systems to improve patient adherence to tuberculosis clinic appointments for diagnosis and treatment","volume":"2014","author":"Liu Q","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"ref107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-019-1014-8","article-title":"Medication adherence influencing factors-an (updated) overview of systematic reviews","volume":"8","author":"Gast A","year":"2019","journal-title":"Systematic reviews"},{"key":"ref108","first-page":"12","article-title":"Medication adherence measures: an overview","author":"Lam WY","year":"2015","journal-title":"Biomed Res Int"},{"issue":"9","key":"ref109","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.cgh.2015.02.024","article-title":"Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity","volume":"13","author":"Hayashi PH","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"16","key":"ref110","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2022.37.e128","article-title":"Analysis of Adverse Drug Reactions to First-Line Anti-Tuberculosis Drugs Using the Korea Adverse Event Reporting System","volume":"37","author":"Chung SJ","year":"2022","journal-title":"J Korean Med Sci"},{"issue":"3","key":"ref111","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(19)30575-4","article-title":"Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials","volume":"20","author":"Campbell JR","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"ref112","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/resp.13346","article-title":"Latent tuberculosis infection: Opportunities and challenges","volume":"23","author":"Chee CB","year":"2018","journal-title":"Respirology"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jclinepi.2020.12.027","article-title":"Language restrictions in systematic reviews should not be imposed in the search strategy but in the eligibility criteria if necessary","volume":"132","author":"Pieper D","year":"2021","journal-title":"J Clin Epidemiol"},{"issue":"7425","key":"ref114","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1136\/bmj.327.7425.1222","article-title":"Joining the DoTS: New approach to classifying adverse drug reactions","volume":"327","author":"Aronson JK","year":"2003","journal-title":"BMJ"},{"issue":"2","key":"ref115","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"ref116","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(16)30199-1","article-title":"Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models","volume":"4","author":"Houben RM","year":"2016","journal-title":"Lancet Glob Health"}],"container-title":["Revista da Sociedade Brasileira de Medicina Tropical"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0037-86822024000100402&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T10:11:44Z","timestamp":1711361504000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0037-86822024000100402&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":116,"alternative-id":["S0037-86822024000100402"],"URL":"https:\/\/doi.org\/10.1590\/0037-8682-0504-2023","relation":{},"ISSN":["1678-9849","0037-8682"],"issn-type":[{"value":"1678-9849","type":"electronic"},{"value":"0037-8682","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"e00402-2024"}}